Literature DB >> 10661909

Intelligence and physical features of children of women with epilepsy.

L B Holmes1, P B Rosenberger, E A Harvey, S Khoshbin, L Ryan.   

Abstract

The teratogenicity of maternal epilepsy has been attributed to several factors, including the antiepileptic drugs taken to prevent seizures during pregnancy, the occurrence of seizures during pregnancy, and the factors in the mother that caused her to have epilepsy. We have addressed the hypothesis that the children of women who have a history of epilepsy (seizure history), but who took no antiepileptic drugs (AED) and had no tonic-clonic seizures in pregnancy, have an increased risk of malformations and diminished intelligence. The frequency of cognitive dysfunction was determined in 57 seizure history and 57 matched control children aged 6-l6 years. The masked evaluation of the children included a physical and neurologic examination and testing with the Wechsler Intelligence Scale for Children-Revised (WISC-R) and a systematic physical examination for the features of the fetal AED syndrome. The evaluation of both parents of each child included a test of reasoning (Ravens Progressive Matrix) and a physical examination. There were no differences between the two groups of children in either IQ scores or physical features; none of the seizure history children was judged to have the "anticonvulsant face" or digit hypoplasia. This study had 80% power to rule out a difference of seven or more IQ points between the two groups, based on a two-sided test at a 5% level of significance. Our confidence in concluding that there was no difference between seizure history and control infants was strengthened by the fact that no statistically significant differences were observed with respect to multiple outcomes, including eight related measures of intelligence. Thirty (53%) of the seizure history mothers resumed taking AED after the birth of the child we evaluated. Additional studies are needed to address the teratogenicity of the antiepileptic drugs as monotherapy. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 10661909     DOI: 10.1002/(SICI)1096-9926(200003)61:3<196::AID-TERA7>3.0.CO;2-T

Source DB:  PubMed          Journal:  Teratology        ISSN: 0040-3709


  12 in total

1.  Use of antiepileptic medications in pregnancy in relation to risks of birth defects.

Authors:  Martha M Werler; Katherine A Ahrens; Jaclyn L F Bosco; Allen A Mitchell; Marlene T Anderka; Suzanne M Gilboa; Lewis B Holmes
Journal:  Ann Epidemiol       Date:  2011-11       Impact factor: 3.797

Review 2.  Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.

Authors:  Jennifer Weston; Rebecca Bromley; Cerian F Jackson; Naghme Adab; Jill Clayton-Smith; Janette Greenhalgh; Juliet Hounsome; Andrew J McKay; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2016-11-07

Review 3.  Neurodevelopmental effects of antiepileptic drugs.

Authors:  Kimford J Meador
Journal:  Curr Neurol Neurosci Rep       Date:  2002-07       Impact factor: 5.081

Review 4.  Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations.

Authors:  James W McAuley; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Antiepileptic drugs during pregnancy: what is known and which AEDs seem to be safest?

Authors:  Page B Pennell
Journal:  Epilepsia       Date:  2008-12       Impact factor: 5.864

Review 6.  Long-term consequences after exposure to antiepileptic drugs in utero.

Authors:  Lisa Forsberg; Katarina Wide
Journal:  Ther Adv Drug Saf       Date:  2011-10

Review 7.  Antiepileptic drugs in women with epilepsy during pregnancy.

Authors:  Evan Gedzelman; Kimford J Meador
Journal:  Ther Adv Drug Saf       Date:  2012-04

Review 8.  Practice parameter update: management issues for women with epilepsy--focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society.

Authors:  C L Harden; K J Meador; P B Pennell; W A Hauser; G S Gronseth; J A French; S Wiebe; D Thurman; B S Koppel; P W Kaplan; J N Robinson; J Hopp; T Y Ting; B Gidal; C A Hovinga; A N Wilner; B Vazquez; L Holmes; A Krumholz; R Finnell; D Hirtz; C Le Guen
Journal:  Neurology       Date:  2009-04-27       Impact factor: 9.910

Review 9.  Management of epilepsy during pregnancy.

Authors:  Dina Battino; Torbjörn Tomson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Malformation rates in children of women with untreated epilepsy: a meta-analysis.

Authors:  Shawn Fried; Eran Kozer; Irena Nulman; Thomas R Einarson; Gideon Koren
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.